Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells

References

• Hu S, Ueda M, Stetson L, et al. A novel glycogen synthase kinase-3 inhibitor optimized for acute myeloid leukemia differentiation activity. Mol Cancer Ther. 2016;15:1485–1494.
   PubMed Web of Science ®Google Scholar
• Iriyama N, Yuan B, Hatta Y, et al. Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation. Cancer Cell Int. 2016;16:37.
   PubMed Web of Science ®Google Scholar
• Ibabao CN, Bunaciu RP, Schaefer DM, et al. The AhR agonist VAF347 augments retinoic acid-induced differentiation in leukemia cells. FEBS Open Bio. 2015;5:308–318.
   PubMed Web of Science ®Google Scholar
• Watts JM, Tallman MS. Acute promyelocytic leukemia: what is the new standard of care? Blood Rev. 2014;28:205–212.
   PubMed Web of Science ®Google Scholar
• Coombs CC, Tavakkoli M, Tallman MS. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J. 2015;5:e304.
   PubMed Web of Science ®Google Scholar
• Warrell Jr RP. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood. 1993;82:1949–1953.
   PubMed Web of Science ®Google Scholar
• Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene. 2003;22:7305–7315.
   PubMed Web of Science ®Google Scholar
• Jensen HA, Bunaciu RP, Varner JD, et al. GW5074 and PP2 kinase inhibitors implicate nontraditional c-Raf and Lyn function as drivers of retinoic acid-induced maturation. Cellr Signal. 2015;27:1666–1675.
   PubMed Web of Science ®Google Scholar
• Bunaciu RP, MacDonald RJ, Gao F, et al. Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment. Oncotarget. 2018;9:4134–4149.
   PubMedGoogle Scholar
• Kim MP, Park SI, Kopetz S, et al. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res. 2009;335:249–259.
   PubMed Web of Science ®Google Scholar
• Logue JS, Morrison DK. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev. 2012;26:641–650.
   PubMed Web of Science ®Google Scholar
• Dos Santos C, Demur C, Bardet V, et al. A critical role for Lyn in acute myeloid leukemia. Blood. 2008;111:2269–2279.
   PubMed Web of Science ®Google Scholar
• Kropf PL, Wang L, Zang Y, et al. Dasatinib promotes ATRA-induced differentiation of AML cells. Leukemia. 2010;24:663–665.
   PubMed Web of Science ®Google Scholar
• Congleton J, MacDonald R, Yen A. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells. Leukemia. 2012;26:1180–1188.
   PubMed Web of Science ®Google Scholar
• Katagiri K, Yokoyama KK, Yamamoto T, et al. Lyn and Fgr protein-tyrosine kinases prevent apoptosis during retinoic acid-induced granulocytic differentiation of HL-60 cells. J Biol Chem. 1996;271:11557–11562.
   PubMed Web of Science ®Google Scholar
• Notario V, Gutkind JS, Imaizumi M, et al. Expression of the fgr protooncogene product as a function of myelomonocytic cell maturation. J Cell Biol. 1989;109:3129–3136.
   PubMed Web of Science ®Google Scholar
• Guerrouahen BS, Futami M, Vaklavas C, et al. Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res. 2010;16:1149–1158.
   PubMed Web of Science ®Google Scholar
• Miranda MB, Redner RL, Johnson DE. Inhibition of Src family kinases enhances retinoic acid induced gene expression and myeloid differentiation. Mol Cancer Ther. 2007;6:3081–3090.
   PubMed Web of Science ®Google Scholar
• Jensen HA, Styskal LE, Tasseff R, et al. The Src-family kinase inhibitor PP2 rescues inducible differentiation events in emergent retinoic acid-resistant myeloblastic leukemia cells. PloS One. 2013;8:e58621.
   PubMed Web of Science ®Google Scholar
• Yen A, Roberson MS, Varvayanis S, et al. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res. 1998;58:3163–3172.
   PubMed Web of Science ®Google Scholar
• Abbas R, Hsyu PH. Clinical pharmacokinetics and pharmacodynamics of bosutinib. Clin Pharmacokinet. 2016;55:1191–1204.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Cortes JE, Kim DW, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123:1309–1318.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567–4576.
   PubMed Web of Science ®Google Scholar
• MacDonald RJ, Shrimp JH, Jiang H, et al. Probing the requirement for CD38 in retinoic acid-induced HL-60 cell differentiation with a small molecule dimerizer and genetic knockout. Sci Rep. 2017;7:17406.
   PubMed Web of Science ®Google Scholar
• Bunaciu RP, Yen A. Activation of the aryl hydrocarbon receptor AhR Promotes retinoic acid-induced differentiation of myeloblastic leukemia cells by restricting expression of the stem cell transcription factor Oct4. Cancer Res. 2011;71:2371–2380.
   PubMed Web of Science ®Google Scholar
• Vultur A, Buettner R, Kowolik C, et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther. 2008;7:1185–1194.
   PubMed Web of Science ®Google Scholar
• Wallace AS, Supnick HT, Bunaciu RP, et al. RRD-251 enhances all-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells. Oncotarget. 2016;7:46401–46418.
   PubMedGoogle Scholar
• Jensen HA, Bunaciu RP, Ibabao CN, et al. Retinoic acid therapy resistance progresses from unilineage to bilineage in HL-60 leukemic blasts. PloS One. 2014;9:e98929.
   PubMed Web of Science ®Google Scholar
• Yen A, Williams M, Platko JD, et al. Expression of activated RAF accelerates cell differentiation and RB protein down-regulation but not hypophosphorylation. Eur J Cell Biol. 1994;65:103–113.
   PubMed Web of Science ®Google Scholar
• Shen M, Yen A. c-Cbl interacts with CD38 and promotes retinoic acid-induced differentiation and G0 arrest of human myeloblastic leukemia cells. Cancer Res. 2008;68:8761–8769.
   PubMed Web of Science ®Google Scholar
• Congleton J, Shen M, MacDonald R, et al. Phosphorylation of c-Cbl and p85 PI3K driven by all-trans retinoic acid and CD38 depends on Lyn kinase activity. Cell Signal. 2014;26:1589–1597.
   PubMed Web of Science ®Google Scholar
• Lamkin TJ, Chin V, Varvayanis S, et al. Retinoic acid-induced CD38 expression in HL-60 myeloblastic leukemia cells regulates cell differentiation or viability depending on expression levels. J Cell Biochem. 2006;97:1328–1338.
   PubMed Web of Science ®Google Scholar
• Nagao T, Kurosu T, Umezawa Y, et al. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. PLoS One. 2014;9:e84746.
   PubMed Web of Science ®Google Scholar
• Raffetto JD, Vasquez R, Goodwin DG, et al. Mitogen-activated protein kinase pathway regulates cell proliferation in venous ulcer fibroblasts. Vasc Endovascular Surg. 2006;40:59–66.
   PubMedGoogle Scholar
• Bunaciu RP, Yen A. 6-Formylindolo (3,2-b)carbazole (FICZ) enhances retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells. Mol Cancer. 2013;12:39.
   PubMed Web of Science ®Google Scholar